FibroBiologics (NASDAQ:FBLG) Receives Hold Rating from D. Boral Capital

D. Boral Capital reiterated their hold rating on shares of FibroBiologics (NASDAQ:FBLG) in a report issued on Thursday morning,Benzinga reports.

A number of other analysts have also commented on FBLG. HC Wainwright reduced their price objective on shares of FibroBiologics to $4.00 and set a “buy” rating for the company in a research note on Thursday, February 26th. Weiss Ratings reissued a “sell (e+)” rating on shares of FibroBiologics in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $5.50.

FibroBiologics Price Performance

Shares of FibroBiologics stock opened at $0.22 on Thursday. FibroBiologics has a 1-year low of $0.19 and a 1-year high of $1.53. The business’s fifty day moving average price is $0.30 and its two-hundred day moving average price is $0.35. The company has a market capitalization of $14.87 million, a P/E ratio of -0.52 and a beta of -0.69.

FibroBiologics’s stock is going to reverse split on the morning of Monday, March 30th. The 1-20 reverse split was announced on Wednesday, March 25th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, March 27th.

FibroBiologics (NASDAQ:FBLG) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($0.03) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.06. On average, research analysts expect that FibroBiologics will post -0.53 earnings per share for the current fiscal year.

Insider Activity

In other FibroBiologics news, CFO Jason Davis bought 70,000 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was bought at an average cost of $0.41 per share, with a total value of $28,700.00. Following the completion of the transaction, the chief financial officer directly owned 70,000 shares of the company’s stock, valued at approximately $28,700. The trade was a ∞ increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In the last three months, insiders bought 191,500 shares of company stock worth $72,893. 13.00% of the stock is owned by insiders.

Institutional Trading of FibroBiologics

A number of institutional investors and hedge funds have recently modified their holdings of FBLG. AQR Capital Management LLC bought a new stake in FibroBiologics in the 1st quarter valued at $29,000. XTX Topco Ltd increased its holdings in shares of FibroBiologics by 160.0% during the 2nd quarter. XTX Topco Ltd now owns 45,945 shares of the company’s stock worth $29,000 after purchasing an additional 28,276 shares during the period. AMG National Trust Bank acquired a new position in shares of FibroBiologics during the fourth quarter valued at about $31,000. Jane Street Group LLC acquired a new position in shares of FibroBiologics during the fourth quarter valued at about $34,000. Finally, Marshall Wace LLP bought a new stake in shares of FibroBiologics in the second quarter valued at about $49,000.

FibroBiologics Company Profile

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc was incorporated in 2021 and is based in Houston, Texas.